Andrographolide inhibits breast cancer through suppressing COX-2 expression and angiogenesis via inactivation of p300 signaling and VEGF pathway

doi:10.1186/s13046-018-0926-9

	Andrographolide inhibits breast cancer through suppressing COX-2 expression and angiogenesis via inactivation of p300 signaling and VEGF pathway
	Peng,Yulin 1; Wang,Yan 1; Tang,Ning 1,3; Sun,Dongdong 1; Lan,Yulong 1; Yu,Zhenlong 1,2; Zhao,Xinyu 1; Feng,Lei 1,2; Zhang,Baojing 1; Jin,Lingling 1
刊名	Journal of Experimental & Clinical Cancer Research
	2018-10-12
卷号	37 期号:1
关键词	Andrographolide COX-2/NF-κB Angiogenesis p300 Breast cancer
ISSN号	1756-9966
DOI	10.1186/s13046-018-0926-9
通讯作者	Ma,Xiaochi(maxc1978@163.com) ; Lv,Chuanzhu(lvchuanzhu677@126.com)
英文摘要	AbstractBackgroundAndrographolide (Andro), a diterpenoid lactone, has been used for treatment of various cancers with less adverse effects. However, the underlying mechanisms regarding its anti-tumor mechanism still remain unclear.MethodsCell viability and proliferation were measured by CCK8 and CFSE dilution assay. The localization of p50/p65 or cytochrome c was determined using confocal immunofluorescence. Streptavidin-agarose pulldown or ChIP assays were used to detect the binding of multiple transactivators to COX-2 promoter. The promoter activity was examined by a dual-Luciferase reporter assay. The functions of Andro on COX-2-mediated angiogenesis were also investigated using human HUVEC cells through tube formation and spheroids sprouting assay. The in vivo anti-tumor efficacy of Andro was analyzed in xenografts nude mice.ResultsThe results indicated that Andro could significantly inhibit the proliferation of human breast cancers, and suppress COX-2 expression at both protein and mRNA levels. Furthermore, Andro could dose-dependently inhibit COX-2-mediated angiogenesis in human endothelial cells. We have also found that Andro significantly promoted the activation of cytochrome c and activated caspase-dependent apoptotic signaling pathway. Our further explorations demonstrated that Andro inhibited the binding of the transactivators CREB2, C-Fos and NF-κB and blocked the recruitment of coactivator p300 to COX-2 promoter. Moreover, Andro could effectively inhibit the activity of p300 histone acetyltransferase (HAT), thereby attenuating the p300-mediated acetylation of NF-κB. Besides, Andro could also dramatically inhibit the migration, invasion and tubulogenesis of HUVECs in vitro. In addition, Andro also exhibited effective anti-tumor efficacy as well as angiogenesis inhibition in vivo.ConclusionIn current study, we explore the potential effects of Andro in suppressing breast cancer growth and tumor angiogenesis, as well as the precise mechanisms. This work demonstrated the potential anti-cancer effects of Andro, indicating that Andro could inhibit COX-2 expression through attenuating p300 HAT activity and suppress angiogenesis via VEGF pathway, and thereby could be developed as an antitumor agent for the treatment of breast cancer.
语种	英语
WOS记录号	BMC:10.1186/S13046-018-0926-9
内容类型	期刊论文
源URL	[http://ir.yic.ac.cn/handle/133337/34486]
专题	中国科学院烟台海岸带研究所
通讯作者	Ma,Xiaochi; Lv,Chuanzhu
作者单位	1. 2. 3.
推荐引用方式 GB/T 7714	Peng,Yulin,Wang,Yan,Tang,Ning,et al. Andrographolide inhibits breast cancer through suppressing COX-2 expression and angiogenesis via inactivation of p300 signaling and VEGF pathway[J]. Journal of Experimental & Clinical Cancer Research,2018,37(1).
APA	Peng,Yulin.,Wang,Yan.,Tang,Ning.,Sun,Dongdong.,Lan,Yulong.,...&Lv,Chuanzhu.(2018).Andrographolide inhibits breast cancer through suppressing COX-2 expression and angiogenesis via inactivation of p300 signaling and VEGF pathway.Journal of Experimental & Clinical Cancer Research,37(1).
MLA	Peng,Yulin,et al."Andrographolide inhibits breast cancer through suppressing COX-2 expression and angiogenesis via inactivation of p300 signaling and VEGF pathway".Journal of Experimental & Clinical Cancer Research 37.1(2018).